ReviewAntioxidants (Basel, Switzerland)2026
Oxidative Stability and Nanoencapsulation of Marine Omega-3 LC-PUFAs for Sustainable Aquaculture and Human Health.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are omega-3 long-chain polyunsaturated fatty acids (LC-PUFAs) that make farmed fish valuable to human health, given their bioactivity and highly unsaturated structure that also renders them exceptionally prone to oxidation during feed manufacture and storage, within the fish, and along the supply chain to the consumer. Preserving the oxidative stability, and hence the biological value, of these fatty acids is therefore a central challenge for sustainable aquaculture, made more acute by the replacement of omega-3-rich, oxidatively buffered fish oil with terrestrial oils that lower LC-PUFA content and shift the pro-/antioxidant balance of aquafeeds. Adopting an integrative feed-to-fish-to-consumer perspective, this review examines the strategies proposed to retain and protect EPA and DHA in farmed fish, distinguishing the physiological requirements of fish from the nutritional targets relevant to humans. We first appraise, comparatively, fish oil replacement, finishing diets and nutritional programming, showing that recovery of EPA and DHA is species-, tissue- and context-dependent and seldom complete, with EPA, a key eicosanoid precursor, preferentially catabolised. Through a focused, reproducible literature search, we then evaluate antioxidant-oriented nanoencapsulation as a means of shielding marine LC-PUFAs from oxidation and improving their stability and bioavailability. Although nanoencapsulation consistently enhances oxidative stability and, in the few in vivo studies available, fish performance, the evidence is constrained by heterogeneous and frequently incomplete physicochemical characterisation, scarce storage stability and in vivo data, and largely unaddressed safety, environmental-fate, regulatory, scalability and consumer-acceptance concerns. We conclude that protecting omega-3 oxidative stability will require combining well-characterised delivery systems with species-appropriate nutrition, and we set out the standardised characterisation, required in vivo validation, and integrated safety and life-cycle assessment needed to realise antioxidant-protective, nanotechnology-enabled aquafeeds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.